Startseite Crystal structure of η6-p-cymene-iodido-(N-isopropyl-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C19H26IN2F6Ru
Artikel Open Access

Crystal structure of η6-p-cymene-iodido-(N-isopropyl-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C19H26IN2F6Ru

  • Joel M. Gichumbi , Bernard Omondi ORCID logo EMAIL logo und Holger B. Friedrich
Veröffentlicht/Copyright: 7. Dezember 2019

Abstract

C19H26IN2F6Ru, triclinic, P1̄ (no. 2), a = 9.240(2) Å, b = 10.019(3) Å, c = 12.689(3) Å, α = 78.921°, β = 81.596(10)°, γ = 83.654°, V = 1136.30(5) Å3, Z = 2, Rgt(F) = 0.0174, wRref(F2) = 0.0440, T = 173 K.

CCDC no.: 1964837

The asymmetric unit of the salt-type title is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Orange block
Size:0.20 × 0.17 × 0.14 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:2.18 mm−1
Diffractometer, scan mode:Bruker Smart Apex-II, φ and ω
θmax, completeness:28.3°, >99%
N(hkl)measured, N(hkl)unique, Rint:17004, 5626, 0.015
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 5236
N(param)refined:271
Programs:Bruker [1], SHELX [2], WinGX/ORTEP [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
C10.34230(19)0.25218(17)0.70043(14)0.0138(3)
C20.3932(2)0.02407(18)0.77376(15)0.0182(3)
H20.4523−0.04540.81390.022*
C30.2694(2)−0.01053(19)0.73865(16)0.0202(4)
H30.2457−0.10270.75350.024*
C40.1804(2)0.0900(2)0.68173(16)0.0201(4)
H40.09670.06750.65550.024*
C50.2159(2)0.22430(19)0.66384(15)0.0175(3)
H50.15510.29580.62730.021*
C60.39037(19)0.38808(17)0.68729(14)0.0146(3)
H60.33550.46620.65320.017*
C70.5638(2)0.53641(17)0.71118(14)0.0156(3)
H70.65560.52580.74620.019*
C80.4519(2)0.6296(2)0.76871(18)0.0253(4)
H8A0.48880.71960.75950.038*
H8B0.35930.63870.73780.038*
H8C0.43520.59050.84600.038*
C100.6023(2)0.5951(2)0.59182(16)0.0253(4)
H10A0.63710.68570.58440.038*
H10B0.67960.53480.55930.038*
H10C0.51490.60250.55490.038*
C110.81503(18)0.21185(18)0.88233(15)0.0158(3)
C120.76943(19)0.07682(18)0.89261(15)0.0160(3)
H120.75000.02310.96260.019*
C130.75308(19)0.02281(18)0.80155(15)0.0167(3)
H130.7274−0.06830.81070.020*
C140.77435(19)0.10265(19)0.69490(15)0.0176(3)
C150.81764(19)0.23640(19)0.68479(15)0.0178(3)
H150.83220.29210.61520.021*
C160.83962(18)0.28840(19)0.77760(15)0.0167(3)
H160.87180.37730.76830.020*
C170.8355(2)0.26487(19)0.98273(15)0.0191(4)
H170.75650.23091.04130.023*
C190.9831(3)0.2031(3)1.0193(2)0.0391(6)
H19A0.99730.23691.08430.059*
H19B0.98390.10341.03570.059*
H19C1.06260.22960.96140.059*
C200.8230(2)0.4203(2)0.96849(17)0.0264(4)
H20A0.83740.44721.03630.040*
H20B0.89820.45680.91060.040*
H20C0.72550.45660.94950.040*
C210.7496(2)0.0468(2)0.59780(16)0.0243(4)
H21A0.7204−0.04660.62100.036*
H21B0.67170.10420.56190.036*
H21C0.84050.04620.54720.036*
N10.51049(16)0.39793(14)0.72382(11)0.0129(3)
N20.43209(16)0.15269(15)0.75287(12)0.0135(3)
P1−0.01712(5)0.32867(5)1.35346(4)0.01770(9)
Ru10.61542(2)0.21849(2)0.79809(2)0.01065(4)
I10.43390(2)0.25309(2)0.97949(2)0.01582(4)
F1−0.17631(14)0.34985(15)1.42094(10)0.0367(3)
F2−0.06014(17)0.19179(15)1.32491(12)0.0408(3)
F30.04199(13)0.24255(13)1.46124(10)0.0267(3)
F40.14242(14)0.30624(16)1.28689(11)0.0358(3)
F50.0292(2)0.46406(14)1.38355(13)0.0490(4)
F6−0.07647(17)0.41510(17)1.24738(11)0.0451(4)

Source of material

To a suspension of [(η6-p-cymene)Ru(μ-I)I]2 (0.2 mmol) in methanol (20 mL) was added the ligand (0.42 mmol). The mixture was stirred at room temperature for 3 h followed by reduction of the solvent volume in vacuo to about (10 mL) before adding NH4PF6 (0.42 mmol). The mixture was then cooled in an ice bath while stirring for 2 h leading to a precipitate, which was collected by filtration. The filtrate was washed with diethyl ether and dried in vacuo. Crystals were grown by the liquid diffusion method by layering a solution of the compound in acetone with hexane and left undisturbed for 2 days. Orange crystals, yield = 80%, m.p. 150 °C (decomp.).

1H NMR (400 MHZ, DMSO-d6). δ [ppm] 9.51 (d, JHH = 5.4 Hz, 1H, Py); 8.80 (s, 1H, CH=N); 8.23–8.21 (M, 1H, Py); 8.15 (d, JHH = 7.2 Hz, 1H, Py); 7.80 (s, 1H, Py); 6.26 (d, JHH = 6.26 Hz, 1H, (p-cyAr)); 6.18 (d, JHH = 6.10 Hz, 1H(p-cyAr)); 5.94 (d, JHH = 6.10 Hz, 1H, (p-cyAr)), 5.89 (d, JHH = 6.30 Hz, 1H, (p-cyAr)), 4.88 (sep, 1H, CH) 2.63 (m, 1H, CH (Me)2); 2.16 (s, 3H, (Me)); 1.59 (d, JHH = 6.80 Hz, 3H, (Me); 1.41 (d, JHH = 6.64 Hz, 3H, (Me)(0.95 (d, JHH = 6.88 Hz, 3H, (Me). 13C NMR (400 MHZ, DMSO-d6). δ [ppm] 165.3 (CH=N), 155.7 (Py), 155.5 (Py); 139.8 (Py); 128.8 (Py); 128.2 (Py); 104.2 (Ar); 103.4 (Ar); 87.6 (Ar); 84.5 (Ar) ; 65.5 (CH) ; 30.5 (Me); 23.8 (Me); 22.3 (Me); 22.1 (Me); 21.30 (Me); 18.4 (Me). IR (solid state):γ (C=N) 1622.1 cm−1. MS (ESI, M/Z): 520.98 [C19H26IN2Ru]+.

Experimental details

Crystal evaluation and data collection were done on a Bruker Smart APEX2 diffractometer equipped with an Oxford Cryostream low temperature apparatus operating at 100(1) K. The structure was solved by direct method using the SHELXS [2] program and refined with SHELXL [2]. All hydrogen atoms were placed in idealized positions and refined in riding models with Uiso assigned the values of 1.2 times those of their parent atoms and the distances of C—H were constrained to 0.93 Å for all the aromatic H atoms, 0.960 Å for methyl hydrogens and 0.98 Å for methine hydrogen. The visual crystal structure information was performed using ORTEP-3 [3].

Comment

Ruthenium half-sandwich complexes have found many applications as metallodrugs and as catalysts in various reactions [4], [5]. Biologically, ruthenium complexes have shown potential as anticancer agents [6], [7] and as antimicrobial agents [6]. In catalysis, ruthenium half-sandwich complexes have found applications in, oxidative transformations of alkanes [4], cleavage of double bonds [8], oxidation of alcohols [9] and in transfer hydrogen of ketones [10].

The title compound is part of our continuing studies of half-sandwich ruthenium(II) complexes [6], [7], [8], [9], [10], [11]. The asymmetric unit contains one cationic ruthenium complex featuring a “pseudo-octahedral three-legged piano stool” structure and one counter anion (see the figure). In this arrangement, the ruthenium centre is coordinated to the N,N′-bidentate ligand, through the N atom of the pyridine moeity and the imine N atom, and one iodido ligand to form the base of the stool while the p-cymene ring acts as the apex of the stool [6], [7], [8], [9], [10]. In the complex, the Ru—N bond distances are 2.0714(14) and 2.0761(14) Å . This value is comparable to those reported for other arene ruthenium complexes with N,N′ donor ligands [4], [5], [6], [7], [8], [9], [10]. The N—Ru—N bond angle is 76.99(6) while those of N—Ru—I are 84.44(4) and 83.95(4)°. These values are close to those reported for related compounds [6], [12]. All C—C, C—N and P—F bond length and angles are in the expected range [6], [7], [8], [9], [10], [11], [12], [13].

Acknowledgements

We wish to extend our sincere thanks to the NRF, THRIP (Grant no. Tp 1208035643) and UKZN (URF) for financial support. Gichumbi, M. Joel thanks Prof. E. N. Njoka for his support.

References

1. Bruker. APEXII. Bruker AXS Inc, Madison, WI, USA (2009).Suche in Google Scholar

2. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

3. Farrugia, L. J.: WinGX and ORTEP for Windows. Appl. Crystallogr. 45 (2012) 849–854.10.1107/S0021889812029111Suche in Google Scholar

4. Gichumbi, J. M.; Friedrich, H. B.: Half-sandwich complexes of platinum complexes of platinum group metals (Ir, Rh, Ru and Os) and some recent biological and catalytic applications. J. Organomet. Chem. 866 (2018) 123–143.10.1016/j.jorganchem.2018.04.021Suche in Google Scholar

5. Kumar, P.; Gupta, R.: Half-sandwich arene ruthenium complexes: synthetic strategies and relevance in catalysis. Chem. Soc. Rev. 43 (2014) 707–733.10.1039/C3CS60189GSuche in Google Scholar PubMed

6. Gichumbi, J. M.; Omondi, B.; Lazarus, G.; Singh, M.; Shaikh, N.; Chenia, H. Y.; Friedrich, H. B.: Influence of halogen substitution in the ligand sphere on the antitumor and antibacterial activity of half-sandwich ruthenium(II) complexes [RuX(η6–arene)(C5H4N—2—CH=N–Ar)]+. Z. Anorg. Allg. Chem. 643 (2017) 699–711.10.1002/zaac.201600427Suche in Google Scholar

7. Thangaval, S.; Paulpandi, M.; Friedrich, H. B.; Murugan, K.; Kalva, S.; Skelton, A. A.: Synthesis, characterization, antiproliferative and molecular docking study of new half sandwich Ir(III), Rh(III) and Ru(II) complexes, J. Inorg. Biochem. 159 (2016) 50–61.10.1016/j.jinorgbio.2016.02.006Suche in Google Scholar PubMed

8. Gichumbi, J. M.; Friedrich, H. B.; Omondi, B.: Synthesis and characterization of piano-stool ruthenium complexes with N,N′- pyridine imine bidentate ligands and their application in styrene oxidation. J. Organomet. Chem. 808 (2016) 87–96.10.1016/j.jorganchem.2016.02.015Suche in Google Scholar

9. Gichumbi, J. M.; Friedrich, H. B.; Omondi, B.: Synthesis and characterization of some new half-sandwich ruthenium(II) complexes with bidentate N,N′-ligands and their application in alcohol oxidation. Inorg. Chim. Acta. 456 (2017) 55–63.10.1016/j.ica.2016.11.014Suche in Google Scholar

10. Gichumbi, J. M.; Friedrich, H. B.; Omondi, B.: Application of arene ruthenium(II) complexes with pyridine-2-carboxaldimine ligands in the transfer hydrogenation of ketones. J. Mol. Catal. A: Chem. 416 (2016) 29–38.10.1016/j.molcata.2016.02.012Suche in Google Scholar

11. Nyawade, E. A.; Friedrich, H. B.; Omondi, B.; Mpungose, P.: Synthesis and characterization of new (η5-cyclopentadienyl) dicarbonylruthenium(II) amine complexes: their application as homogeneous catalysts in styrene oxidation. Organometallics 34 (2015) 4922–4931.10.1021/acs.organomet.5b00564Suche in Google Scholar

12. Betanzos-Lara, S.; Novakova, O.; Deeth, R. J.; Pizarro, A. M.; Clarkson, G. J.; Liskova, B.; Brabec, V.; Sadler, P. J.; Habtemariam, A.: Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity. J. Biol. Inorg. Chem. 17 (2012) 1033–1051.10.1007/s00775-012-0917-9Suche in Google Scholar PubMed

13. Gichumbi, J. M.; Omondi, B.; Friedrich, H. B.: Crystal structure of chlorido-(η6–1-isopropyl-4-methyl benzene)-(1-(pyridin-2-yl)-N-(p-tolyl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C23H26ClF6N2PRu. Z. Kristallogr. NCS 232 (2017) 285–287.10.1515/ncrs-2016-0241Suche in Google Scholar

Received: 2019-10-22
Accepted: 2019-11-11
Published Online: 2019-12-07
Published in Print: 2020-02-25

©2019 Joel M. Gichumbi et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Artikel in diesem Heft

  1. Frontmatter
  2. Synthesis and crystal structure of bis{5-fluorine-2-(((4-(1-(methoxy-imino)ethyl)phenyl) imino)methyl)phenolato-κ2N,O}copper(II), C32H28CuF2N4O4
  3. Redetermination of the crystal structure of N′-(3-ethoxy-2-hydroxybenzylidene)-4-fluorobenzohydrazide monohydrate, C16H17FN2O4
  4. The crystal structure of (E)-N′-(1-(3-chloro-4-fluorophenyl) ethylidene)-2-hydroxybenzohydrazide, C15H12ClFN2O2
  5. Crystal structure of (E)-N-[4-(1H)-imidazolyl phenyl]-(2-methylphenyl)methanimine, C17H15N3
  6. The crystal structure of 1-benzyl-4-(2-(phenylethynyl)phenyl)-1H-1,2,3-triazole, C23H17N3
  7. Crystal structure of catena-poly[{μ2-1,5-bis(diphenylphosphanyl)pentane-κ2P:P′}dichloridocadmium(II)], C29H30CdCl2P2
  8. Crystal structure of methyl (E)-N2-((3-methylquinolin-8-yl)sulfonyl)-Nω-nitro-L-argininate - ethanol (1/1), C19H28N6O7S
  9. The crystal structure of trans-carbonyl-(diphenylcyclohexyl-phosphine-κP)iodidomethyl-(2-oxopyridin-1(2H)-olato-κ2O,O′)rhodium(III), C25H28INO3PRh
  10. Crystal structure of N-(amino(pyrazin-2-yl)methylene)-6-methylpyridin-1-ium-3-carbohydrazonate-κ3O,N,N′)-(dinitrato-κ1O)zinc(II), C12H12N8O7Zn
  11. The crystal structure of dichlorido-(tris(2-benzimidazolylmethyl)amine-κ4N,N′,N′′,N′′′)chromium(III) chloride — methanol (1/3), CrC27H33Cl3N7O3
  12. Crystal structure of catena-poly[aqua(μ4-piperazine-1,4-bis(2-hydroxypropanesulfonato-κ8O,O′:O′,N:N′,O′′:O′′,O′′′))silver(I)], C10H24Ag2N2O10S2
  13. Crystal structure of bis(μ3-oxido)-bis(μ2–2,3,4,5-tetrafluorobenzoato-κ2O:O′)-bis(2,3,4,5-tetrafluorobenzoato-κO)-oktakis(3-chlorobenzyl-κC)tetratin(IV), C84H52Cl8F16O10Sn4
  14. Crystal structure of (E)-1-{4-[(4-fluoro-2-hydroxybenzylidene)amino]phenyl}ethanone O-methyl oxime, C16H15FN2O2
  15. Crystal structure of catena-[(bis(O,O′-diethyl dithiophosphato-S,S′)-μ2-1,2-bis(3-pyridylmethylene)hydrazine-N,N′)zinc(II)], {C20H30N4O4P2S4Zn}n
  16. Crystal structure of methyl 2-(4-(3-iodopyrazolo[1,5-a]pyrimidin-6-yl)phenyl)acetate, C15H12IN3O2
  17. Crystal structure of hexacarbonyl-(μ2-methanoato-k2O:O′)-(μ2–bis(di-p-tolylphosphino)cyclohexylamine-κ2P:P′)dirhenium(I), C42H45NO8P2Re2
  18. The cocrystal structure of 1′-hydroxy-1H,1′H-[5,5′-bitetrazol]-1-olate and 1,10-phenanthrolin-1-ium, C14H10N10O2
  19. The crystal structure of 1-benzyl-2-((4-(tert-butyl)phenyl)ethynyl)pyridin-1-ium bromide,C24H24BrN
  20. Crystal structure of (5,5′-bitetrazole-1,1′-diolate)-bis(1,10-phenanthroline)-copper(II), C26H16CuN12O2
  21. Crystal structure of bis(ammonium) diaqua-tetrakis(4-hydroxybenzoato)-manganese(II) tetrahydrate, [NH4]2[C28H24MnO14] ⋅ 4(H2O)
  22. The crystal structure of 3-chloro-1-hydrazino-2,4,6-trinitrobenzene, C6H4ClN5O6
  23. Crystal structure of catena-[(μ2-pyrazine-κ2N:N′)-bis(O,O′-di-ethyldithiophosphato-κ2S,S′)cadmium(II)], {C12H24CdN2O4P2S4}n
  24. Crystal structure of catena-poly[(μ2-pyrazine-N,N′)-bis(O,O′-di-isopropyldithiophosphato-S,S′)cadmium(II) acetonitrile di-solvate], [C16H32CdN2O4P2S4⋅2(C2H3N)]n
  25. Crystal structure of catena-poly{(μ2-N1,N2-bis[(pyridin-4-yl)methyl]ethanediamide-κ2N:N′)-bis(O,O′-di-isopropyldithiophosphato-κ1S)zinc(II)} — acetonitrile (1/1), C26H42N4O6P2S4Zn⋅C2H3N
  26. Crystal structure of tetraqua-bis(4-(hydroxymethyl)benzoato-κO)cobalt(II), C16H22O10Co
  27. Crystal structure of catena-[(bis(O,O′-diethyl dithiophosphato-S,S′)-μ2-1,2-bis(4-pyridylmethylene)hydrazine-N,N′)cadmium(II)], {C20H30CdN4O4P2S4}n
  28. Crystal structure of catena-poly[(μ2-1,2-bis(3-pyridylmethylene)hydrazine-κ2N:N′)-bis(O,O′-dimethyl dithiophosphato-κ2-S,S′)cadmium(II)], {C16H22CdN4O4P2S4}n
  29. Crystal structure of catena-poly[(bis(O,O′-diethyl dithiophosphato-κ2S,S′)-μ2-1,2-bis(3-pyridylmethylene)hydrazine-κ2N:N′)cadmium(II)], {C20H30CdN4O4P2S4}n
  30. The crystal structure of catena-poly[(E)-2-(((5-((trimethylstannyl)thio)-1,3,4-thiadiazol-2-yl)imino)methyl)phenol], C12H15N3OS2Sn
  31. Crystal structure of dichlorido(N-o-tolyl-1,1-di-p-tolylphosphanamine–κ1P)-(methoxydi-p-tolylphosphane-κ1P)palladium(II), C36H39Cl2NOP2Pd
  32. The crystal structure of the triclinic polymorph of hexameric (trimethylsilyl)methyllithium, C24H66Li6Si6
  33. Crystal structure of bis(hydroxydi(pyridin-2-yl)methanolato-κ3N,N′O)cobalt(III) 7,7,8,8-tetracyanoquinodimethane, C34H22CoN8O4
  34. Synthesis and crystal structure of benzyl 5-oxo-5-phenyl-2-(quinolin-2-yl)pentanoate, C27H23NO3
  35. Crystal structure of 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-(2,2-dichloroacetyl)-3,4-dihydro-2 H-benzo[b][1,4]oxazine-7-carboxylate, C19H19Cl2NO5
  36. Crystal structure of dipentyl 2,5-dihydroxycyclohexa-1,4-diene-1,4-dicarboxylate, C18H28O6
  37. The crystal structure of catena-poly[diaqua-(μ4-5-(benzo[d]thiazol-2-yl)benzene-1,3-dicarboxylate-κ4O,O′:O′′,O′′′)-(μ4-5-(benzo[d]thiazol-2-yl)benzene-1,3-dicarboxylate-κ4O,O′:O′′,O′′′)dicadmium(II)], C30H18Cd2N2O10S2
  38. Crystal structure of 2,7-diiodo-1,3,6,8-tetramethyl-bis(difluoroboron)-1,2-bis((1H-pyrrol-2-yl)methylene)hydrazine, C14H14B2F4I2N4
  39. A dinuclear Eu(III) complex in the crystal structure of dodecaaqua-bis(μ2-4-(1H-tetrazol-5-yl)benzoato-κ2O:O′) bis(5-(4-carboxylatophenyl)tetrazol-1-ide) tetrahydrate, C32H50Eu2N16O24
  40. Crystal structure and anti-inflammatory activity of (3E,5E)-3-(2-fluorobenzylidene)-1-((4-fluorophenyl)sulfonyl)-5-(pyridin-3-ylmethylene)piperidin-4-one, C24H18F2N2O3S
  41. Crystal structure and anti-inflammatory activity of (3E,5E)-3-(2-fluorobenzylidene)-1-((4-acetamidophenyl)sulfonyl)-5-(pyridin-3-ylmethylene)piperidin-4-one-methanol-hydrate (2/1/1), C53H50F2N6O10S2
  42. Crystal structure of 4-dimethylamino-pyridin-1-ium uracil-1-acetate, C13H16N4O4
  43. Crystal structure of dimethylammonium 5-fluorouracil-1-acetate, C8H12N3O4F
  44. Crystal structure of bis(N′-((5-(ethoxycarbonyl)-1H-pyrrol-2-yl)methylene)-N-ethylcarbamohydrazonothioato-κ2N,O)nickel(II), C22H30N8O4S2Ni
  45. Crystal structure of chlorido-(η5-pentamethylcyclopentadienyl)-((bis-pyrazol-1-yl)methane-κ2N,N′) rhodium(III) hexafluorophosphate. (C17H23ClN4RhF6P)
  46. The crystal structure of 5-(benzofuran-2-carbonyl)-N-cyclohexyl-5,6-dihydrophenanthridine-6-carboxamide, C29H26N2O3
  47. The crystal structure of 2-oxo-2H-chromen-4-yl acetate, C11H8O4
  48. The crystal structure of 2-nitroisophthalic acid, C8H5NO6
  49. Crystal structure of 3-fluoro-9-methoxy-4b,5,14,15-tetrahydro-6H-isoquinolino [2′,1′:1,6]pyrazino[2,3-b]quinoxaline, C19H17FN4O
  50. Crystal structure of (4-fluorobenzyl-κC)(bis(2-hydroxyethyl) carbamodithioato-κ2S,S′)(2,2′-imino-diethanolato-κ3N,O,O′)tin(IV), C16H25FN2O4S2Sn
  51. Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-bromophenyl)sulfonyl)-3-(pyridin-4-ylmethylene)-5-(2-(trifluoromethyl)benzylidene)piperidin-4-one, C25H18BrF3N2O3S
  52. Crystal structure and anti-inflammatory activity of (3E,5E)-1-((4-chlorophenyl)sulfonyl)-3-(pyridin-4-ylmethylene)-5-(2-(trifluoromethyl)benzylidene)piperidin-4-one, C25H18ClF3N2O3S
  53. The crystal structure of 3-((1R,2S)-1-methylpyrrolidin-1-ium-2-yl)pyridin-1-ium tetrachloridomanganate(II), C10H16Cl4MnN2
  54. The crystal structure of 3-carboxy-5-methylpyridin-1-ium-2-carboxylate, C8H7NO4
  55. Crystal structure of bis(3-methoxy-N-(1-(pyridin-2-yl)ethylidene)benzohydrazonato κ3O,N,N′)zinc(II), C30H28N6O4Zn
  56. Crystal structure of dichlorido-(4,4′-dichloro-2,2′-bipyridine-κ2N,N′)platinum(II) — acetone (1/1), C13H12Cl4N2PtO
  57. Crystal structure of diethyl 6,12-bis(4-fluorophenyl)-2,10-dimethoxy-3,9-diphenyl-3,9-diazatetracyclo[6.4.0.02,7.04,11]dodecane-1,5-dicarboxylate, C42H42F2N2O6
  58. Synthesis and crystal structure of (1E,3E)-2-hydroxy-5-methylisophthalaldehyde O,O-di(2-((((E)-(2-hydroxynaphthalen-1-yl)methylene)amino)oxy)ethyl) dioxime, C35H32N4O7
  59. The crystal structure of 2-phenyl-4,6-bis(prop-2-yn-1-yloxy)-1,3,5-triazine, C15H11N3O2
  60. Crystal structure of 7-(2-{4-[(4-bromophenyl)methyl]piperazin-1-yl}ethoxy)-2H-chromen-2-one, C22H23BrN2O3
  61. Crystal structure of bis-[N-(3-ethyl-1-pyrazin-2-yl-ethylidene)-3-bromo-benzoic acid-hydrazonato-κ3O,N,N′)]-cadmium(II), C30H28N8O2Br2Cd
  62. Crystal structure of 6-(4-fluorophenyl)-4-methoxy-2H-pyran-2-one, C12H9FO3
  63. Crystal structure of 3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanoic acid, C14H18O4
  64. The crystal structure of 3-bromo-6-methoxy-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, C13H19BBrNO3
  65. The crystal structure of 6-methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate–2,4-dihydroxybenzoic acid (1/1), C30H36O8
  66. The crystal structure of (5-chloro-2-hydroxy-N-(4-methoxy-2-oxidobenzylidene)benzohydrazonato-κ3N,O,O′)-(pyridine-κ1N)copper(II), C20H16ClCuN3O4
  67. Crystal structure of (E)-2-cyano-N′-(1-(3-ethylpyrazin-2-yl)ethylidene)acetohydrazide, C11H3N5O
  68. Crystal structure of (2,7-dihexyl-9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphane), C51H56OP2
  69. Crystal structure of 5-((bis(pyridin-2-ylmethyl)amino)methyl)quinolin-8-ol, C22H20N4O
  70. Crystal structure of 3-(2-(5-(4-fluorophenyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-1-yl)thiazol-4-yl)-2H-chromen-2-one, C28H20FN3O2S
  71. The crystal structure of [(tetra-μ2-2,6-difluorobenzoato-κ2O:O′)-bis-(2,6-difluorobenzoato-κ2O:O′)-bis-(1,10-phenanthroline-κ2N:N′)]dierbium(III) C66H34N4O12F12Er2
  72. Crystal structure of bis(3-chloro-N-(1-(pyrazin-2-yl)ethylidene)benzohydrazonato-k3N,N′,O)nickel(II), C26H20N8O2Cl2Ni
  73. Crystal structure of (E)-3-(3-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)-1-phenyl-1H-pyrazol-4-yl)-1-phenylprop-2-en-1-one, C27H21N5O
  74. Crystal structure of (E)-N′-((4-aminophenyl)sulfonyl)-N,N-dimethylformimidamide, C9H13N3O2S
  75. Crystal structure of η6-p-cymene-iodido-(N-isopropyl-1-(pyridin-2-yl)methanimine-κ2N,N′)ruthenium(II) hexafluorophosphate(V), C19H26IN2F6Ru
  76. Crystal structure of 6-iodo-3-phenyl-2-propylquinazolin-4(3H)-one, C17H15IN2O
  77. Low temperature redetermination of the crystal structure of catena-poly[[tri-4-fluorobenzyltin(IV)]μ2-pyridine-4-carboxylato-κ2N:O], {C27H22F3NO2Sn}n
  78. Crystal structure of bis(2-propyl-1H-benzo[d]imidazol-3-ium) tetrachloridozincate(II), C10H13Cl4N2Zn
  79. The crystal structure of (Z)-3-hydrazono-5-nitroindolin-2-one – dimethyl sulfoxide (1/1), C8H6N4O3
  80. Crystal structure of bis-[N-(1-pyrazin-2-yl-ethylidene)-cyanoacetic acid-hydrazonato-κ3O,N,N′)]-zinc(II), C18H16N10O2Zn
  81. Crystal structure and photochromism of 1-(2,5-dimethyl-3-thienyl)-2-[2-methyl-5-(benzaldoxime)-3-thienyl] perfluorocyclopentene, C23H17F6NOS2
Heruntergeladen am 21.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2019-0786/html
Button zum nach oben scrollen